Welcome to our dedicated page for UpStream Bio news (Ticker: UPB), a resource for investors and traders seeking the latest updates and insights on UpStream Bio stock.
Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody antagonist of the thymic stromal lymphopoietin (TSLP) receptor, for severe respiratory inflammatory diseases. The UPB news feed on Stock Titan highlights company announcements that explain how this single asset is progressing through clinical development and what that may mean for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD).
Investors following UPB can find press releases on positive top-line data from the VIBRANT Phase 2 trial in CRSwNP, where verekitug dosed every 12 weeks met its primary endpoint and key secondary endpoints with a generally well tolerated safety profile. News items also cover structural and mechanistic data presented at scientific congresses, detailing how verekitug binds the TSLP receptor, prevents TSLP binding, and outcompetes TSLP even in the presence of preformed receptor complexes.
Additional updates include reports on enrollment and design of the VALIANT Phase 2 trial in severe asthma, the VENTURE Phase 2 trial in COPD, and the VALOUR long-term extension study. Financial results releases, furnished via Form 8-K, summarize research and development spending related to verekitug and provide context on the company’s cash position and operating expenses.
News coverage also tracks Upstream Bio’s participation in healthcare and biopharma investor conferences, where management discusses clinical progress and upcoming milestones. For anyone monitoring UPB stock or the development of TSLP receptor-targeted therapies in respiratory disease, this page aggregates the company’s official news and regulatory communications in one place.
Upstream Bio (Nasdaq:UPB) presented additional Phase 2 VIBRANT data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at the AAAAI 2026 meeting. WOCF-adjusted analyses showed a placebo-adjusted NPS reduction of -1.95 (p < 0.0001) and NCS reduction of -0.96 (p < 0.0001) at Week 24.
The trial (n=81) also reported a 76% reduction in need for surgery or systemic corticosteroids (p=0.03), an acceptable safety profile with no SAEs observed, and plans to initiate Phase 3 registrational trials in CRSwNP and severe asthma.
Upstream Bio (Nasdaq: UPB) will present additional analyses from the Phase 2 VIBRANT trial of verekitug (UPB-101) in chronic rhinosinusitis with nasal polyps (CRSwNP) during a late-breaking poster session at AAAAI Congress 2026.
The poster will report efficacy and safety analyses adjusted for concomitant rescue therapy use. Presentation by Joseph Han, MD is scheduled for March 1, 2026, 9:45–10:45 a.m. EST in Convention Center Level 2, Hall E (Poster L60).
Upstream Bio (Nasdaq: UPB) announced CEO Rand Sutherland will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston on March 4 (Fireside Chat at 9:50 a.m. ET) and Leerink Partners Global Healthcare Conference in Miami on March 9 (Fireside Chat at 1:40 p.m. ET).
Live webcasts will be available under the Events tab on the Investors section of Upstream Bio’s website, and replays will be posted after the presentations.
Upstream Bio (Nasdaq: UPB) reported positive top-line Phase 2 VALIANT results for verekitug in severe asthma, showing statistically significant reductions in annualized asthma exacerbation rate (AAER): 56% reduction at 100 mg q12w and 39% at 400 mg q24w versus placebo.
Verekitug also improved lung function (FEV1: +122 mL and +139 mL at week 60) and reduced FeNO (20.4 ppb and 26.3 ppb), was generally well tolerated, has >90% rollover into the VALOUR LTE, and will advance toward Phase 3 in severe asthma and CRSwNP following regulatory interactions.
Upstream Bio (Nasdaq: UPB) will webcast top-line results from the Phase 2 VALIANT trial of verekitug on February 11, 2026 at 8:00 a.m. ET. The global, randomized, double-blind, placebo-controlled trial enrolled 478 patients with severe asthma and tested three dosing regimens versus placebo for up to 60 weeks.
Live access and a replay will be available on the company’s investor events page.
Upstream Bio (Nasdaq: UPB) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 2:15 p.m. PT. Rand Sutherland, MD, Chief Executive Officer, will deliver the presentation. A live webcast will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event, and a replay will be posted on the company website after the presentation.
Upstream Bio (Nasdaq: UPB) announced that CEO Rand Sutherland, MD will participate in two investor conferences in December 2025: a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025 at 4:30 p.m. ET, and a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Thursday, December 4, 2025 at 10:25 a.m. ET.
Live webcasts will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of each presentation, and replays will be posted after the events.
Upstream Bio (Nasdaq: UPB) reported Q3 2025 results and program progress for verekitug, a TSLP receptor antagonist targeting severe respiratory diseases.
Key clinical highlights: VIBRANT Phase 2 in CRSwNP met its primary endpoint with a placebo-adjusted endoscopic NPS reduction of -1.8 (p<0.0001), nasal congestion improvement -0.8 (p=0.0003), and a 76% reduction in need for surgery or systemic corticosteroids (p=0.03). VALIANT Phase 2 top-line data in severe asthma are expected in Q1 2026; VENTURE COPD trial enrollment is ongoing after first patient dosed in July 2025.
Financials: cash, equivalents and short-term investments of $372.4M expected to fund operations through 2027; Q3 R&D expense $33.0M; Q3 net loss $33.7M.
Upstream Bio (Nasdaq: UPB) said CEO Rand Sutherland, MD will participate in three investor events in November 2025: Truist Securities BioPharma Symposium in New York on Nov 6, 2025 at 8:10 a.m. ET (panel); Stifel 2025 Healthcare Conference in New York on Nov 11, 2025 at 9:20 a.m. ET (presentation); and TD Cowen Immunology and Inflammation Summit (virtual) on Nov 12, 2025 at 10:30 a.m. ET (fireside chat).
Live webcasts of the Stifel and Cowen presentations will be available under the Events tab in the Investors section of Upstream Bio’s website on the day of each event, and replays will be posted after the presentations.
Upstream Bio (Nasdaq: UPB) presented structural and mechanistic data for verekitug, their TSLP receptor-targeting treatment for inflammatory diseases, at the European Respiratory Society Congress. The data revealed verekitug's unique mechanism of action, showing high-affinity binding to the TSLP receptor and ability to outcompete TSLP binding even with preformed heterodimeric receptor complexes.
The company recently reported successful Phase 2 results in chronic rhinosinusitis with nasal polyps, demonstrating significant effects with 12-week dosing intervals. Additional Phase 2 data for severe asthma is expected in Q1 2026. The preclinical findings suggest verekitug's receptor-targeting approach may offer advantages over current TSLP ligand-targeting therapies, potentially enabling less frequent dosing compared to existing biologics.